Progressive Multifocal Leukoencephalopathy

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA label_change · 2008-09-25
European Medicines Agency recommends update of product information of Tysabri and risk of progressive multifocal leukoencephalopathy (PML)
EMA recommends updating the product information for Tysabri to reflect risks of progressive multifocal leukoencephalopathy (PML).